Kleinzelliges Lungenkarzinom

Multicenter Randomized Open-Label Phase III Study Comparing Efficacy, Safety, and Tolerability of Conventional Carboplatin Plus Etoposide Versus Dose-Intensified Carboplatin Plus Etoposide Plus Lenograstim in Small-Cell Lung Cancer in “Extensive Disease” Stage

“…However, the median and 2-year survival are only 8 to 12 months and 10% to 20%, respectively. 1,2 There are trials showing a survival benefit with dose-intensified regimens in SCLC. Dose-intensified vincristine, ifosfamide, carboplatin, and etoposide (V-ICE) showed improved survival compared with standard dosing (median survival 443 vs. 351 days).…”